Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

RESPIRE · Artificial intelligence enabled electrospinning approach to fight pulmonary cancer

HORIZONStatus: SIGNED1 September 202628 February 2030EU funding €445,402Call HORIZON-MSCA-2024-PF-01

Pulmonary cancer is the leading cause of cancer deaths worldwide. Surgery is associated with high morbidity and operative mortality. One of the main causes of the poor survival rate is cancer relapse at the surgical resection margins. Thus, developing a strategy to minimize the local recurrence rate of lung cancer efficiently is greatly needed. Nanotechnology-assisted approaches, such as nanoparticles (NPs) and nanofibers (NFs) obtained via electrospinning could enable novel strategies to fabricate better performing implantable devices, including localized drug delivery systems. Many working parameters affect the final outcomes in electrospinning and different fibrous architectures can be generated, much is still to be understood to precisely control, and ultimately predict the mechanical, physico-chemical, and bioactive properties of the resulting meshes, which are essential in pulmonary tissues. The Postdoctoral Fellowship Researcher (PFR) has studied biodegradable fibers as drug delivery systems in her Ph.D. and Post Doc and herein aims to develop a biodegradable nanofibrous patch based on elastin (i.e., the native component of the pulmonary tissues) containing chemotherapeutics via electrospinning/electrospray. To achieve this ambitious goal, the PFR needs to learn multiscale materials design and artificial intelligence to precisely match the mechanical properties of lung tissue, which will be addressed during the outgoing phase at MIT. PFR will also investigate the encapsulation of chemotherapy and immunotherapy inside electrosprayed NPs, will model release mechanisms at MIT and will analyze drug release effectiveness in an in vitro model at UTRGV (i.e., secondment) to be used for a biologic assessment in the returning phase at the UNIPI. The multidisciplinary approach (engineering, biology, materials and medical sciences), will accelerate the development of innovative clinically oriented prototypes and will contribute to the ER’s scientific and personal.

Consortium · 4 organisations

coordinator

UNIVERSITA DI PISA

IT · €445,402

associatedPartner

LINARI ENGINEERING SRL

IT

associatedPartner

MASSACHUSETTS INSTITUTE OF TECHNOLOGY

US

associatedPartner

The University of Texas Rio Grande Valley

US

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.